Vantis, a San Jose, CA-based medical technology company, raised $5M in Safe (Simple Agreement for Future Equity) financing.
With this funding, which followed a total raise of $24M to date from individuals and NIH grants, the company intends to advance the field of interventional cardiology and improve patient outcomes.
Led by CEO Jason Turner, and Chief Medical Officer Tim Fischell, MD, Vantis Vascular is a medtech company dedicated to improving vascular interventions via performance-driven technologies. Its flagship products in development include the CrossFAST™ Integrated Microcatheter Guide Extension System and the CrossSHOCK™ Intravascular Lithotripsy (IVL) System.
The CrossFAST Integrated Microcatheter Guide Extension System, with 2-in-1 DuoPro™ Interlocking Technology, provides interventionalists with enhanced control and maneuverability to traverse the most calcific and tortuous anatomies, while the CrossSHOCK IVL System utilizes a low profile, micro electrode design to optimize the IVL experience, while striving for a safer, faster and more efficient approach to treating calcified arteries. Both products serve large and growing cardiovascular markets, including the multibillion IVL opportunity.
Products are currently in development and are not commercially available for sale in any geography.
Commenting on the news, Jason Turner said: “This financing underscores the confidence of our investors in our vision, experienced management team, and the potential of our technologies to drive innovation and make a lasting impact in vascular interventions. This round will aid to accelerate our development efforts, while supporting the near-term commercial launch of our CrossFAST system.”
FinSMEs
21/05/2024